Organigram Holdings Inc. (TSE:OGI – Free Report) – Equities research analysts at Atb Cap Markets cut their FY2025 earnings estimates for Organigram in a note issued to investors on Wednesday, August 13th. Atb Cap Markets analyst F. Gomes now anticipates that the company will post earnings of $0.07 per share for the year, down from their prior forecast of $0.10. The consensus estimate for Organigram’s current full-year earnings is $0.16 per share. Atb Cap Markets also issued estimates for Organigram’s FY2027 earnings at $0.06 EPS.
Organigram Trading Down 6.1%
TSE OGI opened at C$2.01 on Monday. Organigram has a 52 week low of C$1.22 and a 52 week high of C$2.84. The firm has a 50 day moving average of C$1.95 and a two-hundred day moving average of C$1.77. The company has a quick ratio of 2.62, a current ratio of 3.36 and a debt-to-equity ratio of 3.07. The stock has a market capitalization of C$248.32 million, a PE ratio of -4.25, a price-to-earnings-growth ratio of 0.42 and a beta of 1.13.
Organigram Company Profile
Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.
Featured Articles
- Five stocks we like better than Organigram
- Asset Allocation Strategies in Volatile Markets
- Silver Prices Up, But Endeavour’s Profit Still Elusive
- 3 Fintech Stocks With Good 2021 Prospects
- Cocoa Futures Send Hershey Stock Lower, Dip Opportunity?
- How to Calculate Return on Investment (ROI)
- Smart Money Piles Into GRID ETF on Trillion-Dollar Power Upgrade
Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.
